Adagio Medical Completes Enrollment for Pivotal VT Cryoablation Trial

Wednesday, Oct 1, 2025 9:56 am ET1min read
ADGM--

Adagio Medical has completed enrollment for its pivotal VT cryoablation trial. The company is developing ablation technologies for treating cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio includes the iCLAS, vCLAS, and Cryopulse catheters, all of which share the same ULTC cryoablation console. The company aims to expand its product offerings and indications in the European Union market.

Adagio Medical Completes Enrollment for Pivotal VT Cryoablation Trial

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet